

2025 PARTNERSHIP PROGRAMS

The latest updates in clinical services; innovations & research initiatives

www.BardDiagnostics.com



Volume 1: January 2025

Screening & Diagnostic Innovations:

TURNKEY GENE TESTING & EPIGENETICS PROGRAMS

For 2025, BardDiagnostics launched a streamlined and affordable upgrade to Gene Testing. Our customized program is designed to support personalized health by targeting GENETIC PREDISPOSITION, OCCUPATIONAL EXPOSURES and BIO-AGE data. As a supplement to our clinical imaging solutions, we have expanded our clinical partners to include specialized GENOMICS TESTING LABS for the continued advancement of our patient care and our prevention and early detection programs. Patients will receive a full review of their results including complete guidance from a qualified medical advisor explaining lab reports. Our medical consultants will also provide a personalized strategy for optimizing the patient's health.



health, hormones, cancers, exercise and injury, bone density.

3A) PHARMACOGENOMIC TESTING: Also known as PGx testing, this study of the patient's genomes interprets SNPs in genes associated with medication response, including adverse reactions and effectiveness. This is vital for anyone seeking answers about what prescriptions are actually working, and which ones fail in expected response.

For any patient in need of a comprehensive report on their current state of health on a genetic level, **THE FIRST PHASE** program establishes the patient's actual blueprint and the foundation of a personalized approach to minimizing exposure risks and optimizing health.

1A) FUNDAMENTAL GENE TEST: We start with this easy to implement (cheek swab) DNA standard lab test from one of our top clinical testing labs to identify and interpret any inherited mutations for common cancers. This includes (but is not limited to) breast, prostate, pancreatic, ovarian, colorectal, stomach, and melanoma) and cardiovascular disease.

2A) NUTRIGENOMIC TESTING: As part of personalized care, this highly beneficial test option helps identify genetic variations leading to lifestyle–disease associations and management. Genomic testing and interpretation of SNPs in many systems underlying health, including the processing of environmental toxins, nutrition, sleep, heart disease, brain health, mood, diabetes, inflammation, oxidative stress, mitochondrial

BIOLOGICAL & HEALTH IMPACT TESTING PROGRAM

This next segment is typically for patients who have concerns over JOB-RELATED OR ENVIRONMENTAL EXPOSURES. When it comes to toxic exposures, health hazards exist in lesser or greater quantity - especially in the more dangerous jobs (ie. firefighting, construction, engine work).

For the many Americans who dedicated an extended period of their careers to potentially toxic exposures, this comprehensive clinical testing program offers direct insight into their genetic predispositions for potentially adverse responses to occupational exposures. The selected testing also identifies predisposition to common cancers, chronic diseases, and other health issues.

1B) TOXIN TESTING: Specialized testing to assess current levels

assess current levels of a wide variety of toxins encountered



in the workplace and home environments, with personalized strategies for supporting your internal detoxification systems to reduce their levels and impact.


2B) EPIGENETIC TESTING: Epigenetic testing and interpretation to assess how environmental exposures, diet, and lifestyle are interacting with your genetic predispositions, <u>impacting real-time gene expression</u> and health risks including how fast your cells are aging, general cancer and disease risks, immune health, smoking and alcohol exposures.

3B) FUNCTIONAL LAB TESTING: Additional specialized lab tests to assess areas identified as potential targets of toxins, directly or indirectly. Personalized to each client, these can include assessments of hormones, mitochondria, oxidative stress, microbiome, stress, sleep and more.



QUANTITATIVE IMAGING

For the independent health practice promoting personalized healthcare, **BARD** DIAGNOSTICS complements your visionary practice with a complete diagnostic package consisting of a full gene testing program and individualized radiology services & clinical imaging. Our catalog of personalized imaging led by world-class radiologists and sonologists offer added peace of mind to patients of every level of health concern. We also advocate the use of safe (nonradiation) non-invasive biometric technologies and recognized medical imaging that's compatible with all current clinical reporting standards. Our diagnostic experts are recognized "disease detectives" who work directly with each patient, offering a complete and accurate pathological analysis with almost zero wait time.



Endometrial Cancer - Nodal Metastasis (25 yrs post rx)

2ND OPINION IMAGING PROGRAM

Historically, a significant population of our patients are referred by cancer specialists or recently diagnosed individuals in search of an expert opinion beyond their initial scans. Our SECOND OPINION SCAN provides a deeper dive scan using advanced ultrasound features (ie. 3D Doppler Ultrasound, Elastographpy), analyzing the existing tumor, inflammatory disorder or infected areas. This program is also comprised of:

- **ACTIVE SURVEILLANCE:** for anyone who wants to monitor a low-grade cancer not needing surgery yet
- **RECURRENCE DETECTION:** for anyone who ended cancer treatment (chemo/radio) and wants to check for potential postop issues
- **EARLIER DETECTION** (breast screening): for women ages 20-39 whose insurance coverage does not qualify them for standard mammogram.

THE POWER OF TODAY'S ULTRASOUND IMAGING

A sonogram was once known as 'the baby camera', allowing the physician to safely access a real-time view of a fetus. Since the 70's, the industry collectively invested in significant R&D to elevate the power of ultrasound imaging for an endless array of diagnostic and analytical needs. Its major advantage of a hand-held, portable transducer tracking a subdermal disorder in real-time is a priceless benefit to any physician in search of fast, reliable answers. Offering these benefits alongside measurable (quantitative) scanning powers closes the circle between "what could be wrong" and "what is DEFINITIELY there".

For more information on our Diagnostic Imaging and Personalized Gene Testing programs, visit:

www.BardDiagnostics.com or contact us at:

212.355.7017



2025 PARTNERSHIP PROGRAMS

The latest updates in clinical services; innovations & research initiatives

www.BardDiagnostics.com

ئريئ

Meet our new specialist:

ROBERTA KLINE, MD

Director of Clinical Testing and Personalized Women's Health



DR. ROBERTA KLINE is a physician-scientist and genetics consultant who is dedicated to improving our approach to aging and physical health. Her professional history is comprised of specialized work as an ObGyn physician and a Functional Medicine & Genomics Specialist. As a clinical advocate, Dr. Kline has spearheaded innovative approaches to translating cuttingedge science into improved health for women through education, research, clinical care and communication.

Since the spring of 2022, Dr. Kline was nominated into a directorial position by the AngioInstitute(501c3) to co-develop the Women's Health Collaborative- a national coalition of professionals in support of women's health and wellness programs. Her contribution led to publishing, education and outreach initiatives and were set into motion to implement

public services for the underserved women in communities across the U.S.

As a licensed physician in New York and New Mexico, one of her latest achievements is the launch of multi-state prototype of the Gene Testing & Epigenetics programs of BardDiagnostics for the Better Aging and Fight Recurrence campaigns. This service set offers patient insight into health predispositions of cancer and chronic health issues and is expected to launch additional partnership locations in 7 other states by mid-summer of 2025.

Dr. Kline also maintains her scientific consultancy in support of medical technology developers and private research projects. She is also highly sought-after as an educator on a wide range of topics around women's health and gene expression. She has held keynote speaking roles in various medical conferences, cancer foundation events and has been featured guest in health-related talk shows and podcasts. She has presented to a variety of



audiences including the general public, industrial groups and healthcare professionals.

For more information on Dr. Roberta Kline and the Gene Testing & Epigenetics program, visit: www.barddiagnostics.com - or contact her office at: 505.675.0444